A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Iberdomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms EXCALIBER-RRMM
- Sponsors Celgene Corporation
- 03 Oct 2023 Planned End Date changed from 26 Jan 2033 to 25 Jun 2032.
- 03 Oct 2023 Planned primary completion date changed from 18 Jun 2027 to 18 Mar 2026.
- 15 Jun 2023 Trial design presented at the 28th Congress of the European Haematology Association.